IGI Laboratories Ranked Number 256 Fastest Growing Company In North America On Deloitte 2014 Technology Fast 500™

BUENA, N.J., Nov. 13, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced it ranked No. 256 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. IGI grew 382 percent from 2009 to 2013.

"At IGI we are excited about our transition and transformation from 2009 to 2013 from a topical contract manufacturing company to a specialty generic pharmaceutical company and it is rewarding for our success in that transformation and revenue growth to be recognized with a prestigious Deloitte Technology Fast 500 Award," said Jason Grenfell-Gardner, IGI's President and CEO.  "Our future is bright, as we continue to expand our product portfolio and execute our "TICO" strategy, focused on the topical, injectable, complex and ophthalmic generic pharmaceutical markets."

"The companies ranked on the 2014 Deloitte Technology Fast 500 continue to set the bar for their industry higher each year," said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications leader. "There are so many exciting products and smart thought leaders driving this list. We congratulate the Fast 500 companies and look forward to seeing them continue their momentum into 2015."

About Deloitte's 2014 Technology Fast 500™
Technology Fast 500, conducted by Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2009 to 2013.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.

About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

Logo - http://photos.prnewswire.com/prnh/20130827/MM70487LOGO

SOURCE IGI Laboratories, Inc.

Copyright 2014 PR Newswire